Literature DB >> 17070361

Mucinous adenocarcinoma of the prostate does not confer poor prognosis.

Brian R Lane1, Cristina Magi-Galluzzi, Alwyn M Reuther, Howard S Levin, Ming Zhou, Eric A Klein.   

Abstract

OBJECTIVES: To report a series of patients with mucinous (colloid) adenocarcinoma (MC) at prostatectomy who were treated at a single institution from 1987 to 2005. MC is a rare form of prostate cancer reported in some cases to have a more aggressive clinical course than conventional adenocarcinoma (AC).
METHODS: Radical prostatectomy specimens with mucinous features were identified from a database of 3613 consecutive patients. Each case was reviewed again by a single pathologist who confirmed the diagnosis of MC in 14 patients. MC was defined by the presence of pools of extracellular mucin in more than 25% of the tumor. Eighteen additional cases were identified in which the mucinous component occupied only a small portion of the tumor and were referred to as AC with focal mucin (AFM). The biochemical and overall survival of 26 patients with MC or AFM who had completed > or = 6 months of follow-up was analyzed using Kaplan-Meier estimates.
RESULTS: No patients with MC or AFM died of disease, and 11 (91.7%) of 12 patients with MC and 9 (64.3%) of 14 patients with AFM were clinically and biochemically free of disease. No significant difference was found in biochemical recurrence or overall survival between those with MC or AFM and a matched group of patients with AC.
CONCLUSIONS: We report what we believe to be the largest published series of cases of MC (n = 14) with a median overall follow-up of 6.4 years. MC appears to behave clinically in a similar fashion to AC, with no statistically significant difference in biochemical failure or survival.

Entities:  

Mesh:

Year:  2006        PMID: 17070361     DOI: 10.1016/j.urology.2006.04.028

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

1.  [The 2014 consensus conference of the ISUP on Gleason grading of prostatic carcinoma].

Authors:  G Kristiansen; L Egevad; M Amin; B Delahunt; J R Srigley; P A Humphrey; J I Epstein
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

Review 2.  The pathology of unusual subtypes of prostate cancer.

Authors:  Jing Li; Zhe Wang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

Review 3.  Grading of Prostate Cancer: Past, Present, and Future.

Authors:  Andres Matoso; Jonathan I Epstein
Journal:  Curr Urol Rep       Date:  2016-03       Impact factor: 3.092

4.  Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.

Authors:  Kenneth A Iczkowski; Kathleen C Torkko; Gregory R Kotnis; R Storey Wilson; Wei Huang; Thomas M Wheeler; Andrea M Abeyta; Francisco G La Rosa; Shelly Cook; Priya N Werahera; M Scott Lucia
Journal:  Am J Clin Pathol       Date:  2011-07       Impact factor: 2.493

Review 5.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

6.  Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features.

Authors:  Antonio C Westphalen; Fergus V Coakley; John Kurhanewicz; Galen Reed; Zhen J Wang; Jeffry P Simko
Journal:  AJR Am J Roentgenol       Date:  2009-09       Impact factor: 3.959

7.  Metastatic Mucinous Adenocarcinoma of the Prostate with PSA Value of 8.6 ng/mL at 5-Year-Followup after Prostatectomy, Radiotherapy, and Androgen Deprivation.

Authors:  Christos Kalaitzis; Michael Koukourakis; Stilianos Giannakopoulos; Alexandra Giatromanolaki; Efthimios Sivridis; Athanasios Bantis; Stavros Touloupidis
Journal:  Case Rep Urol       Date:  2014-01-29

8.  Case Report: Prostate Adenocarcinoma With Mucinous Features of Normal-Level Serum PSA, Atypical Imaging, Biopsy-Negative, and Peculiar Urethrocystoscopic Manifestation.

Authors:  Yao Zhang; Hua Shen; Kai Liao; Weili Wu; Jiuming Li; Hongbo Yu; Hongfei Wu; Zengjun Wang
Journal:  Front Oncol       Date:  2020-12-23       Impact factor: 6.244

9.  Radical exenteration surgery is curative in locally advance mucinous prostatic adenocarcinoma involving bladder and rectum.

Authors:  Vincent S W Koo; Naing N K Lynn; Mark F Saxby
Journal:  J Surg Case Rep       Date:  2010-06-01

Review 10.  Grading of prostatic adenocarcinoma: current state and prognostic implications.

Authors:  Jennifer Gordetsky; Jonathan Epstein
Journal:  Diagn Pathol       Date:  2016-03-09       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.